TY - JOUR
T1 - Antiangiogenic agents after first line and sorafenib plus chemoembolization
T2 - A systematic review
AU - Casadei Gardini, Andrea
AU - Santini, Daniele
AU - Aprile, Giuseppe
AU - Silvestris, Nicola
AU - Felli, Emanuele
AU - Foschi, Francesco Giuseppe
AU - Ercolani, Giorgio
AU - Marisi, Giorgia
AU - Valgiusti, Martina
AU - Passardi, Alessandro
AU - Puzzoni, Marco
AU - Silletta, Marianna
AU - Brunetti, Oronzo
AU - Cardellino, Giovanni Gerardo
AU - Frassineti, Giovanni Luca
AU - Scartozzi, Mario
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Transarterial chemoembolization (TACE) is the standard treatment for intermediate stage, although the combination of TACE with sorafenib may theoretically benefit HCC patients in intermediate stage. Owing to the significant antiangiogenic effect of sorafenib and the limitation of TACE, it is rational to combine them. Though the strategy of combining TACE and sorafenib has been increasingly used in patients with unresectable HCC but the current evidence is controversial and its clinical role has not been determined yet. In first-line therapy, patients receiving sorafenib had increased overall survival and progression free survival. Therefore several antiangiogenic agents have entered clinical studies on HCC, many with negative results. This review discusses the current drug development for patients with HCC and role of TACE plus sorafenib.
AB - Transarterial chemoembolization (TACE) is the standard treatment for intermediate stage, although the combination of TACE with sorafenib may theoretically benefit HCC patients in intermediate stage. Owing to the significant antiangiogenic effect of sorafenib and the limitation of TACE, it is rational to combine them. Though the strategy of combining TACE and sorafenib has been increasingly used in patients with unresectable HCC but the current evidence is controversial and its clinical role has not been determined yet. In first-line therapy, patients receiving sorafenib had increased overall survival and progression free survival. Therefore several antiangiogenic agents have entered clinical studies on HCC, many with negative results. This review discusses the current drug development for patients with HCC and role of TACE plus sorafenib.
KW - Antiangiogenic
KW - Hepatocellular carcinoma
KW - Second line
KW - Tace
KW - Transcatheter arterial chemoembolization
UR - http://www.scopus.com/inward/record.url?scp=85030120891&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030120891&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.19449
DO - 10.18632/oncotarget.19449
M3 - Review article
AN - SCOPUS:85030120891
VL - 8
SP - 66699
EP - 66708
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 39
ER -